JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB269816

GSK126, EZH2 methyltransferase inhibitor

Be the first to review this product! Submit a review

|

(2 Publications)

MW 526.7 Da. Potent inhibitor EZH2 methyltransferase inhibitor (Ki = 93 pM). Selective (>150-fold) versus EZH1. Greater than 1000-fold selective against a panel of 20 other human methyltransferases including both SET-domain-containing and non-SET-domain-containing methyltransferases. Decreases global H3K27me3 levels. Inhibits B-cell lymphoma cell proliferation in vitro. Inhibits EZH2 mutant tumor growth in xenograft models. Reactivates silenced PRC2 target genes and inhibits the proliferation of EZH2 mutant DLBCL cell lines and corresponding xenografts mice. Literature suggests that GSK126 is a potential treatment for EZH2 mutant lymphoma (McCabe et al).

View Alternative Names

AD 003, Alpha N-terminal protein methyltransferase 1A, C9orf32, CHET9, ChET 9 protein, Chromatin precipitated E2F target 9 protein, Chromosome 9 open reading frame 32, EED protein, EED, mouse, homolog of, EED_HUMAN, ENX-1, EZH2_HUMAN, EZH2b, Embryonic ECTODERM development protein homolog, Embryonic ectoderm development, Embryonic ectoderm development isoform a, Embryonic ectoderm development protein, mouse, homolog of, Enhancer of zeste 2, Enhancer of zeste homolog 2, Enhancer of zeste homolog 2 (Drosophila), Enhancer of zeste, Drosophila, homolog 2, Enx 1h, Histone-lysine N-methyltransferase EZH2, JJAZ1, Joined to JAZF1 protein, KIAA0160, KMT 6, KMT6A, Lysine N-methyltransferase 6, MGC9169, Methyltransferase like 11A, Methyltransferase-like protein 11A, N-terminal RCC1 methyltransferase, NRMT, NTM1A_HUMAN, NTMT1, OTTHUMP00000235483, OTTHUMP00000235484, OTTHUMP00000235485, Polycomb protein SUZ12, Polycomb protein eed, SUZ12 polycomb repressive complex 2 subunit, SUZ12_HUMAN, Suppressor of zeste 12 homolog, Suppressor of zeste 12 protein homolog, WAIT-1, WD protein associating with integrin cytoplasmic tails 1, WVS, WVS2, X-Pro-Lys N-terminal protein methyltransferase 1A, enhancer of zeste 2 polycomb repressive complex 2 subunit, hEED

1 Images
Chemical Structure - GSK126, EZH2 methyltransferase inhibitor (AB269816)
  • Chemical Structure

Lab

Chemical Structure - GSK126, EZH2 methyltransferase inhibitor (AB269816)

Chemical structure of GSK126, EZH2 methyltransferase inhibitor, 1346574-57-9

Key facts

CAS number

1346574-57-9

Form

Solid

form

Molecular weight

526.7 Da

Molecular formula

C<sub>3</sub><sub>1</sub>H<sub>3</sub><sub>8</sub>N<sub>6</sub>O<sub>2</sub>

PubChem

68210102

Nature

Synthetic

Biochemical name

(S)-1-(sec-Butyl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3-methyl-6-(6-(piperazin-1-yl)pyridin-3-yl)-1H-indole-4-carboxamide

Biological description

Potent inhibitor EZH2 methyltransferase inhibitor (Ki = 93 pM). Selective (>150-fold) versus EZH1. Greater than 1000-fold selective against a panel of 20 other human methyltransferases including both SET-domain-containing and non-SET-domain-containing methyltransferases. Decreases global H3K27me3 levels. Inhibits B-cell lymphoma cell proliferation in vitro. Inhibits EZH2 mutant tumor growth in xenograft models. Reactivates silenced PRC2 target genes and inhibits the proliferation of EZH2 mutant DLBCL cell lines and corresponding xenografts mice. Literature suggests that GSK126 is a potential treatment for EZH2 mutant lymphoma (McCabe et al)

Canonical smiles

CCC(C)N1C=C(C2=C(C=C(C=C21)C3=CN=C(C=C3)N4CCNCC4)C(=O)NCC5=C(C=C(NC5=O)C)C)C

Isomeric smiles

CC[C@H](C)N1C=C(C2=C(C=C(C=C21)C3=CN=C(C=C3)N4CCNCC4)C(=O)NCC5=C(C=C(NC5=O)C)C)C

InChi

InChI=1S/C31H38N6O2/c1-6-22(5)37-18-20(3)29-25(30(38)34-17-26-19(2)13-21(4)35-31(26)39)14-24(15-27(29)37)23-7-8-28(33-16-23)36-11-9-32-10-12-36/h7-8,13-16,18,22,32H,6,9-12,17H2,1-5H3,(H,34,38)(H,35,39)/t22-/m0/s1

InChiKey

FKSFKBQGSFSOSM-QFIPXVFZSA-N

IUPAC Name

1-[(2S)-butan-2-yl]-N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-3-methyl-6-(6-piperazin-1-ylpyridin-3-yl)indole-4-carboxamide

Properties and storage information

Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
-20°C
Appropriate long-term storage conditions
-20°C
Handling instructions

Need more advice on solubility, usage and handling? Please visit our our product support page for more details.

|

Refer to SDS for further information.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

The target KMT6 also known as EZH2 is an important player in the regulation of chromatin structure through its function as a methyltransferase. EZH2 along with EED and SUZ12 forms the core components of the Polycomb Repressive Complex 2 (PRC2). The molecular mass of the EZH2 protein is approximately 85 kDa. This protein is expressed in various tissues with notable presence in lymphoid tissues and the central nervous system. There exist numerous EZH2 inhibitors targeting this protein such as GSK126 which highlight its importance in biological processes and potential for therapeutic intervention.
Biological function summary

The PRC2 complex involving EZH2 EED and SUZ12 regulates gene expression by catalyzing the trimethylation of histone H3 on lysine 27 (H3K27me3) an important epigenetic marker for gene repression. The complex controls genes involved in development differentiation and proliferation. EZH2's activity is notably high in stem cells and proliferating cells due to its role in maintaining chromatin compaction and transcriptional silencing.

Pathways

The EZH2 protein and its associated PRC2 complex are elements of the epigenetic regulatory pathways controlling gene expression. They significantly impact the Wnt signaling pathway which influences embryonic development and cell growth. Additionally EZH2 interacts with other proteins such as histone deacetylases (HDACs) to facilitate tighter chromatin binding and gene silencing highlighting its role within the chromatin modification network.

Dysregulation of EZH2 contributes to several cancers including lymphomas and prostate cancer. Overexpression of EZH2 results in unchecked cellular proliferation and tumor growth. Moreover chronic obstructive pulmonary disease (COPD) has shown links to this protein where altered expression affects inflammatory responses. Proteins such as BRCA1 in prostate cancer showcase the broader interaction network that EZH2 participates in during disease states. Clinical trials involving inhibitors like GSK126 aim to mitigate the oncogenic activities of this methyltransferase highlighting its relevance in therapeutic development.

Product protocols

Publications (2)

Recent publications for all applications. Explore the full list and refine your search

Heliyon 10:e32553 PubMed39183840

2024

Effects of EZH2 inhibitor, trichostatin A, and 5-azacytidine combinatorial treatment on osteogenic differentiation of dental pulp stem cells.

Applications

Unspecified application

Species

Unspecified reactive species

Edit Hrubi,László Imre,Csaba Hegedüs

International journal of molecular sciences 23: PubMed35955891

2022

PAR-Induced Harnessing of EZH2 to β-Catenin: Implications for Colorectal Cancer.

Applications

Unspecified application

Species

Unspecified reactive species

Shoshana Sedley,Jeetendra Kumar Nag,Tatyana Rudina,Rachel Bar-Shavit
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com